Overview
The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative
Description
The present randomized clinical trial aims at investigating two approaches (autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative) when performed for vertical soft tissue augmentation at sites with peri-implant soft tissue dehiscences. Clinical, volumetric, ultrasonographic, and patient-reported outcomes will be evaluated at different time points up to 1 year.
Eligibility
Inclusion criteria:
- Age ≥ 18 years
- Periodontally and systemically healthy
- Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth)
- Presence of single functional dental implant in the anterior with a PSTD
- Implants diagnosed as healthy (Berglundh et al., 2018)
Exclusion criteria are:
- Contraindications for surgery
- Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing
- Patients pregnant or attempting to get pregnant (self-reported)
- Untreated periodontitis
- Untreated peri-implant mucositis or peri-implantitis (Berglundh et al., 2018)
- Smoking, defined as self-reported daily habit. Occasional smokers won't be excluded
- History of soft tissue grafting at the implant site within the last 6 months